IGE-ANTIGEN COMPLEXES (IGE-ACS) IN SEPSIS: PRECISION IMMUNOTHERAPY FOR IMMUNE BALANCE AND INFECTION CONTROL

Sepsis triggers a powerful hyper-inflammatory response intended to eliminate infection, but this immune
overactivation can lead to life-threatening organ failure. Efforts to control inflammation frequently raise the risk of secondary infections, presenting a major therapeutic challenge. IgE-antigen complexes (IgE-ACs) have emerged as a potential solution by engaging CD23 receptors on multiple immune cell types—including M2 macrophages, B cells, dendritic cells, and monocytes—to rebalance the immune system. This targeted immunotherapy can suppress harmful hyper-inflammation, promote tissue repair, and enhance protection against secondary infections. By fine-tuning both innate and adaptive responses, IgE-ACs offer a promising approach for restoring immune equilibrium and improving outcomes in sepsis. This review examines the underlying mechanisms, current evidence, and clinical potential of IgEACs, and discusses a prophetic example to illustrate the opportunities and hurdles of this innovative strategy.